Bio & Pharma
Costco sells Celltrion's Yuflyma Low WAC in US
The S.Korean firm's autoimmune disease drug was registered in the Costco Membership Prescription Program
By Aug 13, 2024 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
Samsung’s Ballie, LG's Q9 AI robots steal the show at IFA 2024
Daishin Securities shelves main office building sale to NH-Amundi
S.Korea's NPS opens fourth overseas office in Silicon Valley
SK Ecoplant sells off stake in Ascend Elements for $98 million
South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now available for purchase at Costco in the US.
According to Celltrion, Yuflyma was registered earlier this month under the Costco Membership Prescription Program (CMPP) at a low wholesale acquisition cost (WAC).
CMPP is a program that allows Costco members to purchase medications at discounted prices at in-store pharmacies or affiliated pharmacies.
Starting this month, uninsured Costco members and their dependents can purchase Yuflyma at a discounted price in Costco stores and affiliated pharmacies across the United States at a reduced wholesale price.
The National Center for Health Statistics of the US Centers for Disease Control and Prevention (CDC) reported that the number of uninsured individuals in the US reached 27 million in the first quarter of 2024.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Bio & PharmaCelltrion gets FDA nod for Keytruda copy's phase 3 clinical trials
Aug 12, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion's Zymfentra joins US insurance-covered drug lists
Aug 06, 2024 (Gmt+09:00)
1 Min read -
Bio & PharmaCelltrion’s new plant in Songdo poised for commercial production
Jul 23, 2024 (Gmt+09:00)
2 Min read -
Bio & PharmaCelltrion's Remsima SC breaks 20% market share in Europe
Jul 17, 2024 (Gmt+09:00)
1 Min read
Comment 0
LOG IN